/ANIP

ANI Pharmaceuticals Inc

ANIP

$70.19USD↓-1.78%-1.27 today

MARKET CAP

1.6B

P/E (TTM)

8.3x

FWD P/E

7.4x

DAY RANGE

$70 – $72

52W RANGE

$70

$99

AI Summary

Stalk

TrimMedium

ANIP remains in Stage 4 decline with price below declining EMAs and a persistent Lower Highs & Lower Lows pattern, reinforcing medium-term bearish bias. RSI is near oversold but lacks reversal structure, so selling is best deferred into rallies to the declining 9-day and 20-day EMAs around the $73–$74 region. A decisive hold above the 20-day EMA would invalidate this bias.

↑Q2’26 revenue $266M (+26% YoY); adjusted EBITDA $71.6M (+32% YoY)
↑Cortofan gel drove $117.1M in Q2, +43% YoY, set to be ~60% of 2026 sales
↓Revenue guidance trimmed to $520–540M amid below-expectation Cortofan uptake

Full analysis →

Buying

4

institutions

Selling

7

institutions

New Positions

0

this quarter

Filing Period

Q1 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	2.96 M	244.92 M	+211.15 K	+15.9%	0.00%
MM Millennium Management LLC Q2 2026	SELL	507.21 K	41.99 M	+-84.81 K	-7.8%	0.02%
JC Jpmorgan Chase & Co Q2 2026	BUY	232.95 K	19.68 M	+12.79 K	+21.3%	0.00%
JH Janus Henderson Group Plc Q1 2026	BUY	219.10 K	16.85 M	+211.32 K	+2642.3%	0.00%
CA Citadel Advisors LLC Q2 2026	SELL	104.78 K	8.67 M	+-17.00 K	-7.4%	0.00%
MG Man Group Plc Q2 2026	SELL	80.50 K	6.66 M	+-128.20 K	-58.5%	0.01%
RT Renaissance Technologies LLC Q2 2026	SELL	63.70 K	5.27 M	+-122.40 K	-63.1%	0.01%
HS Hussman Strategic Advisors, Inc. Q2 2026	SELL	31.50 K	2.61 M	+-21.00 K	-35.4%	0.60%
AC Aqr Capital Management LLC Q2 2026	BUY	29.50 K	2.44 M	+10.66 K	+68.5%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	2.48 K	205.46 K	+-4.99 K	-64.2%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	65.00	5.38 K	+-48.00	-38.1%	0.00%